Molecular Partners (MOLN) announced the formation of a Scientific Advisory Board for its radiopharmaceuticals, chaired by Prof. Ken Herrmann, Chair of the Department of Nuclear Medicine at University Hospital Essen, Germany. The SAB also includes: radiopharmaceutical industry executive James Cook, previously founder and CEO of Evergreen Theragnostics and U.S. Chief Operating Officer at Advanced Accelerator Applications, where his team commercially launched Lutathera and Netspot; radiochemist Prof. Jason Lewis, Ph.D., the Emily Tow Chair in Oncology at Memorial Sloan Kettering Cancer Center and a Deputy Director of the Sloan Kettering Institute; and medical oncologist and nuclear medicine specialist Prof. Michael Morris, M.D., Steven A. Greenberg Chair in Prostate Cancer Research and Prostate Cancer Section Head at the Memorial Sloan Kettering Cancer Center.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOLN:
- Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
- Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
- Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting
- Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
- Molecular Partners presents updated data from Phase 1/2a trial of MP0533